Yanhua Liu’s research while affiliated with Ningxia Medical University and other places

... MDSCs promote tumor immune evasion primarily by secreting factors such as IL-10 and TGF-β and interacting with T cells and other immune cells, posing a significant challenge in cancer immunotherapy. The development of carrier-free nanoparticles, like gemcitabine-celecoxib nanoparticles (GEM-CXB NP), provides novel approaches for chemoimmunotherapy in BC [45]. Therefore, therapeutic strategies targeting MDSC signaling pathways remain a focal point for future research. ...

Reference:

A Systematic Review of Immune Cell Roles in Breast Cancer Immunotherapy

... Another significant alteration in exhausted CD8 + T cells is the disruption of amino acid metabolism. The availability of key amino acids, such as glutamine, arginine, and tryptophan, is limited inside the TME 72 . Decreased uptake and utilization of these amino acids hinders the synthesis of nucleotides and polyamines critical for T cell function 73,74 . ...

Reference:

The mechanisms and clinical significance of CD8+ T cell exhaustion in anti-tumor immunity

... These exosomes can be loaded with immune adjuvants to enhance tumor immunogenicity and improve immunotherapeutic outcomes . A key advantage of nanomedicine in personalized immunotherapy is its ability to overcome tumor heterogeneity, a significant challenge in achieving consistent treatment responses across patient populations [72][73][74]. Nanoparticles can be engineered to carry multiple therapeutic agents simultaneously, allowing for combinational delivery that targets various tumor pathways. For example, dendrimers have been explored as nanocarriers for siRNA, monoclonal antibodies, and chemotherapeutics, providing a multifaceted approach to disrupt tumor growth and induce an immune response . ...

Reference:

Nanomedicine-Driven Advances Enhancing Checkpoint Inhibition and CAR-T Therapies in Cancer Immunotherapy

... Others authors employed pH-induced release, such as Cao et al. (2023). By complexing CXB with Poly-L-arginine arranged in micelles, it was expected that the acidic environment of the tumor microenvironment would promote the drug release and subsequent inhibition of the COX-2 related immunosuppressive profile [89]. ...

Reference:

Advances, limitations and perspectives in the use of celecoxib-loaded nanocarriers in therapeutics of cancer

... PVP, lecithin, and PEG 400). A prolonged pain relief was reported with all MLX nanosuspensions compared to the control (MLX in solution) in a hind paw incision rat model, which is a common pain in vivo model for RA [32,33]. IV/infusion administration of NCs entails invasiveness and pain at the injection site that hamper therapeutic adherence, requiring a health care facility for the therapeutic follow-up. ...

Reference:

Recent advances in nanocrystals for arthritis drug delivery

... However, numerous challenges can be encountered, including protein adsorption, the influence of physical forces, and rapid clearance, which can obstruct effective biodistribution and drug delivery under normal physiological conditions [57,58]. The goal of developing nanoparticles is to overcome the deficiency of traditional drug delivery systems by eliminating diverse biological obstacles across patient groups and disorders [59,60]. The formulations for pH-dependent drug release use polymers whose characteristics change in response to local pH levels; while preserving stable drug loading at non-target tissues, they also provide target-specific drug release. ...

Reference:

Send Orders for Reprints to reprints@benthamscience.net Drug Delivery Letters, XXXX, XX, 1-18 1 Unlocking the Role of pH-Sensitive Nanoparticles in the Targeted Management of Different Types of Ulcers

... Notably, HSA fusion technology has led to the development of various long-acting protein drugs now approved for treating diseases such as type II diabetes and hemophilia [8]. Additionally, HSA serves as a universal target for various antibody drugs, effectively extending their half-life in vivo by binding to HSA [9,10]. Therefore, HSA is not only an approved drug carrier but is Si-Yuan Hu and Wen Lin contributed equally to this work. ...

Reference:

Molecular mechanism of enhancing antitumor activity through the interaction between monosaccharides and human serum albumin

... Liquideliquid phase separation (LLPS) refers to the phenomenon that homogeneous solution divides into two liquid phases with the process of molecular self-assembly, one rich and one poor in solute (Fraccia & Zanchetta, 2021;Huang et al., 2023Huang et al., , 2024Xu et al., 2021;Zhao et al., 2023). Particles with various micro/nano structures can be generated by reasonably adjusting process parameters of LLPS Wang et al., 2022). ...

Reference:

A novel energy-efficient way to prepare solid lipid microspheres loaded with nanoscale drugs by combining LLPS and in-situ crystallization

... A number of studies have shown that interventions that target certain cells involved in liver fibrosis can slow down or even reverse the progression of liver fibrosis and can significantly reduce the development of severe chronic liver disease. [5][6][7] Liver fibrosis is currently being treated by protecting normal liver cells, 8 inhibiting hepatic stellate cells (HSCs) activation, 9 decreasing extracellular matrix synthesis and secretion, 10 and reducing liver inflammation. Interferons (INF; INF-γ), 11 anti-HBV nucleotides and their analogues, 12 endothelin receptor A antagonists, 13,14 angiotensin receptor blockers, and extracts of natural products such as colchicine 15 and silymarin 16 are commonly used in the treatment of liver fibrosis, with some success. ...

Reference:

Berberine-Loaded PVCL-PVA-PEG Self-Assembled Micelles for the Treatment of Liver Fibrosis

... Artesunate (ART) is a natural small molecule compound that shows promising potential in post-transplant immunotherapy [4]. Previous research has indicated that ART regulates inflammasome activity by inhibiting the Toll-like receptor-4 (TLR-4) signaling pathway, suppresses inflammation-related signaling pathways, and promotes the polarization of macrophages to the M2 phenotype [5,6]. Mycophenolate mofetil (MMF) acts on lymphocyte proliferation, reducing T cell proliferation and activation, and modulating the Type 1 CD4 + T cells (Th1)/Type 2 CD4 + T cells (Th2) balance. ...

Reference:

Artesunate-mycophenolate Mofetil Dimer Micelles Alleviate Allogeneic Skin Graft Rejection by Inhibiting the TLR-4 Pathway in Macrophages